EUCTR2019-004523-21-LT进行中（未招募）1 期
A Phase 2 Study to Evaluate the Sensitivity and Specificity of DBV1605, a Ready to Use Atopy Patch Test for the Diagnosis of Non-Immunoglobulin E Mediated Cow’s Milk Allergy in Children. - APTITUDE
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •DISEASE GROUP
- •Male or female subjects aged >6 months to =24 months at Screening Visit. Age from >28 days to =24 months at Screening Visit after Safety Review Committee (SRC) recommendations are given.
- •Subjects with a history of symptoms that are consistent with non-IgE mediated CMA as per Investigator's assessment, by either:
- •o Two or more gastrointestinal symptoms (vomiting, diarrhea, persistent distress/colic, regurgitation, constipation), that lasted at least 1 week within 1 month prior to Screening Visit
- •o Blood in stool,
- •Subjects with any type of diet containing dairy products with cow's milk protein (e.g. cow's milk consumption, cow's milk partial elimination, partially hydrolyzed milk) prior Screening Visit or who have started a cow's milk elimination diet not more than 4 weeks prior to Screening Visit.
- •Subjects with a negative cow's milk SPT: mean wheal diameter <3 mm and negative control <1 mm.
- •CONTROL GROUP
- •Subjects may be included in the control group only if they meet, among other criteria, the following inclusion criteria:
- •Male or female subjects aged >28 days to =24 months at Screening/Visit 1,
- •Subjects having no medical history of any type of allergy, including no history of IgE-mediated allergic reactions to cow's milk and with no medical history of any food allergy in their family (parents, sibling),
- •Subjects who tolerate at least 200 mL of cow's milk or equivalent dairy foods daily within 4 weeks prior to Screening/Visit 1.
- •Subjects with negative cow's milk SPT: mean wheal diameter <3 mm and negative control <1 mm.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 230
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •criteria is within the study protocol)
- •DISEASE GROUP
- •1 Subjects with an established diagnosis of non-IgE mediated CMA made by a physician upon cow's milk protein challenge.
- •2 Breast-fed subjects at Screening Visit.
- •3 Subjects on a cow's milk protein-free diet including an AA-based formula or an extensively hydrolyzed formula initiated more than 4
- •weeks prior to Screening Visit.
- •4 Subjects with a history of confirmed FPIES or Heiner's syndrome.
- •5 Any contraindication to a cow's milk challenge, in particular subjects with a history of severe anaphylactic reaction to cow's milk. Severe
- •anaphylaxis is defined as Grade 3 of the Anaphylaxis Staging System, including:
- •Severe hypoxia, persistent hypotension or more than 20% drop in blood pressure, neurological compromise, or
- •Cyanosis or SpO2 = 92% at any stage, confusion, cardiovascular collapse, loss of consciousness, bradycardia, cardiac arrest.
- •6 Subjects with a convincing history of IgE-mediated CMA.
- •8 Subjects with diagnosis of asthma or recurrent wheezing that fulfills any of the following criteria:
- •- Uncontrolled asthma or recurrent wheezing (as per Global Initiative for Asthma (GINA) guidelines).
- •- Asthma or recurrent wheezing that is considered uncontrolled per GINA guidelines or has had modifications in their asthma or wheezing
- •controller medication within 3 months prior Screening Visit.
- •10 Known hypersensitivity to any of the DBV1605 components (except to milk proteins).
- •11 Known hypersensitivity to any component of the food challenge formula (except to milk proteins).
- •12 A history of any immunotherapy for CMA.
- •15 Any disorder in which epinephrine is contraindicated such as congenital cardiac malformation, uncontrolled hypertension, or serious
- •ventricular arrhythmias.
- •17 Treatment with antihistamines within 1 to 7 days (depending on halflife and specified in APPENDIX 3) prior to Screening Visit or inability to
- •discontinue antihistamines for the minimum wash-out periods required prior to SPT or food challenges.
- •18 Treatment with topical steroid applied on the back within 30 days prior to Screening Visit.
研究者
相似试验
进行中（未招募）
1 期
A clinical study to assess DBV1605 for the diagnosis of cow's milk allergy in childreon-Immunoglobulin E Mediated Cow's Milk AllergyMedDRA version: 20.0Level: LLTClassification code 10011240Term: Cow's milk allergySystem Organ Class: 100000004870EUCTR2019-004523-21-ITDBV Technologies S.A.230
招募中
1 期
MK-4280 and Pembrolizumab in Hematologic MalignanciesCTIS2023-503587-17-00Merck Sharp & Dohme LLC140
进行中（未招募）
1 期
MK-4280 and Pembrolizumab in Hematologic MalignanciesHematologic malignanciesMedDRA version: 21.1Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 100000004864EUCTR2018-001461-16-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.84
进行中（未招募）
1 期
MK-4280 and Pembrolizumab in Hematologic MalignanciesHematologic malignanciesMedDRA version: 21.1Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 100000004864EUCTR2018-001461-16-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.84
招募中
2 期
A Phase II Study to Investigate the Efficacy and Safety of Oral intake of Anamorelin in Patients After Total GastrectomyAfter Total GastrectomyJPRN-jRCTs041230012Bando Etsuro65